IRIS
Pizzato, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.059
EU - Europa 520
AS - Asia 316
SA - Sud America 8
AF - Africa 7
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 3.914
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.056
IT - Italia 205
SG - Singapore 171
UA - Ucraina 93
CN - Cina 83
FI - Finlandia 59
SE - Svezia 47
GB - Regno Unito 41
DE - Germania 31
ID - Indonesia 20
VN - Vietnam 20
RU - Federazione Russa 10
TR - Turchia 10
BG - Bulgaria 5
CZ - Repubblica Ceca 5
JO - Giordania 5
NL - Olanda 5
BR - Brasile 4
FR - Francia 4
ZA - Sudafrica 4
CL - Cile 3
IN - India 3
BY - Bielorussia 2
CA - Canada 2
EU - Europa 2
IE - Irlanda 2
NO - Norvegia 2
SI - Slovenia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
AZ - Azerbaigian 1
BE - Belgio 1
CH - Svizzera 1
DK - Danimarca 1
EC - Ecuador 1
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
IL - Israele 1
KZ - Kazakistan 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MU - Mauritius 1
MX - Messico 1
MY - Malesia 1
Totale 3.914
Salva come PNG Salva come JPEG
Città #
Fairfield 508
Chandler 281
Ashburn 263
Woodbridge 249
Seattle 224
Jacksonville 219
Wilmington 188
Cambridge 176
Houston 159
Singapore 142
Columbus 103
Ann Arbor 96
Princeton 84
San Mateo 81
Trento 72
New York 38
Beijing 28
Como 26
Helsinki 23
San Diego 23
Dearborn 20
Jakarta 20
London 15
Munich 15
Dong Ket 12
Rome 10
Santa Clara 10
San Paolo di Civitate 9
Verona 9
Boardman 7
Izmir 7
Los Angeles 7
Moscow 7
Milan 6
Turin 6
Washington 6
Bremen 5
Dallas 5
Fort Worth 5
Fremont 5
Guangzhou 5
Sofia 5
Brno 4
Brugherio 4
Düsseldorf 4
Hefei 4
Jinan 4
Riva Del Garda 4
Volargne 4
Irvine 3
Islington 3
Johannesburg 3
Kilburn 3
Prescot 3
Springfield 3
Aberdeen 2
Altamura 2
Amsterdam 2
Aparecida de Goiânia 2
Busto Arsizio 2
Cernusco sul Naviglio 2
Dublin 2
Lagundo 2
Lappeenranta 2
Lyon 2
Minsk 2
Nanjing 2
Napoli 2
Norwalk 2
Padova 2
Pisa 2
Tolmin 2
Toronto 2
Vicenza 2
Villa Lagarina 2
Almaty 1
Arnsberg 1
Baku 1
Baotou 1
Barletta 1
Brasília 1
Cape Town 1
Changsha 1
Chengdu 1
Chicago 1
Council Bluffs 1
Cupertino 1
Des Moines 1
Ferrara di Monte Baldo 1
Frederiksberg 1
Hebei 1
Hyderabad 1
La Canada Flintridge 1
Las Vegas 1
Lawrence 1
Mexico City 1
Mountain View 1
New Bedfont 1
Nuremberg 1
Olcenengo 1
Totale 3.290
Salva come PNG Salva come JPEG
Nome #
SERINC5 as a new restriction factor for human immunodeficiency virus and murine leukemia virus 149
SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins 136
The antagonism of HIV Nef to SERINC5 particle infectivity restriction involves the counteraction of virion-associated pools of the restriction factor 130
HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation 120
Retroviral factors promoting infectivity. 116
The Potency of Nef-Mediated SERINC5 Antagonism Correlates with the Prevalence of Primate Lentiviruses in the Wild 115
A bipartite structural organization defines the SERINC family of HIV-1 restriction factors 111
Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration 110
The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles 104
S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3 102
Galanin pathogenic mutations in temporal lobe epilepsy 99
Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. 98
The antiviral activity of rodent and lagomorph SERINC3 and SERINC5 is counteracted by known viral antagonists 95
Effect of High-Energy Milling on the Dissolution of Anti-HIV Drug Efavirenz in Different Solvents 92
Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. 90
Insertion of targeting domains into the envelope glycoprotein of Moloney murine leukemia virus (MoMLV)-based vectors modulates the route of mCAT-1-mediated viral entry. 88
TRIM5 is an innate immune sensor for the retrovirus capsid lattice. 87
Gene Therapy of Glioblastoma Multiforme with a Bicistronic Retroviral Vector Expressing Human IL-2 and HSV-tK. 85
Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. 84
Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors. 83
Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles. 83
Mechanical activation of Efavirenz: the effects on the dissolution and inhibitory behavior 83
A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. 82
Effect of differential growth conditions on the dTTP pool size in herpes simplex virus-infected Vero cells. 81
Progress with retroviral gene vectors. 79
SARS-CoV-2 and the Host Cell: A Tale of Interactions 78
Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors. 77
The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α. 77
Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection. 75
Localization to detergent-resistant membranes and HIV-1 core entry inhibition correlate with HIV-1 restriction by SERINC5 73
Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. 72
Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75. 72
Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. 70
MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1. 69
Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. 68
Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions. 66
Centriolar distal appendages activate the centrosome-PIDDosome-p53 signalling axis via ANKRD26 66
Determination of HPRT mutant frequency and molecular analysis of T-lymphocyte mutants derived from coke-oven workers. 65
Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix. 63
A Community Study of SARS-CoV-2 Detection by RT-PCR in Saliva: A Reliable and Effective Method 63
The activity of Nef on HIV-1 infectivity. 62
Herpes simplex virus chronically infected human T lymphocytes are susceptible to HIV-1 superinfection and support HIV-1 pseudotyping. 50
Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. 43
Retrovirus vectors. 40
Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve 37
Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer 35
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity 30
Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity 27
Viral particles imaging through evanescent wave scattering in a total internal reflection laser microscope 22
Host Restriction Factors Modulating HIV Latency and Replication in Macrophages 22
Prospective epidemiological, molecular, and genetic characterization of a novel coronavirus disease in the Val Venosta/Vinschgau: the CHRIS COVID-19 study protocol 20
SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals 19
The impact of infection risk communication format on tourism travel intentions during COVID-19 19
Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals 18
Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine 15
Influence of Different Glycoproteins and of the Virion Core on SERINC5 Antiviral Activity 15
A Conserved Acidic Residue in the C-Terminal Flexible Loop of HIV-1 Nef Contributes to the Activity of SERINC5 and CD4 Downregulation 13
Trends and symptoms of SARS-CoV-2 infection: a longitudinal study on an Alpine population representative sample 4
Totale 4.047
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.474
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 322
Totale 20.796
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020638 0 0 0 0 105 68 116 94 117 46 35 57
2020/2021726 9 69 30 96 102 44 48 56 46 74 99 53
2021/2022481 22 32 8 20 12 31 7 106 48 49 59 87
2022/2023607 63 68 6 69 52 87 9 54 113 35 31 20
2023/2024332 20 20 18 20 34 84 21 22 5 13 12 63
2024/2025415 17 11 75 247 65 0 0 0 0 0 0 0
Totale 4.047